Intrinsiqs

Is Novavax, Inc. overvalued?

Novavax, Inc. (NVAX) — key valuation metrics and fundamentals.

No verdict
Price
$10.80
Fair value
—
Current P/E
—
Normal P/E
—
Market cap
$1.78B
Dividend yield
0.0%
Return on equity
159.9%
Sector
Healthcare

See the full interactive analysis →

Fair value compares NVAX's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 24 Sep 2026.